Traditionally, the treatment of motor/locomotor dysfunctions and associated impairments in pa-tients with spinal cord injury (SCI) or Parkinson’s disease (PD) has primarily relied upon invasive surgical interventions (e.g., decompression, stabilization, ablation) and/or chronic drug therapies (e.g., controlled-release levodopa, oxybutynin, baclofen, ropinirole, and gabapentin). While ap-proaches like deep brain stimulation and epidural or brain implants offer undeniable break-throughs, the therapeutic landscape has evolved substantially in recent years to encompass less invasive, safer, and flexible alternatives such as transcutaneous neuromodulation and technolo-gy-assisted, artificial intelligence (AI)-enhanced rehabilitation devices controllable by voice and/or gatekeepers. Furthermore, increasing evidence suggests that specific botanical extracts naturally containing neurobiologically active molecules may serve as additional aids for phar-macologically optimizing motor or locomotor function recovery. This review reports recent evi-dence suggesting that safe new approaches, particularly used as combination therapies, can elicit meaningful effects in the area of on-demand motor/locomotor function recovery. These findings contradict the conventional assumption that exclusively surgical, pharmaceutical, stem cell, and other invasive approaches (e.g., direct stimulation with neurally implanted electrodes) can re-store functions in patients with SCI or PD. From a clinical perspective, the integration of these innovative non-invasive or minimally invasive strategies may represent both effective and safer therapeutic options for individuals with neurological diseases or trauma engaged in exercising with state-of-the-art next-generation rehabilitation technology (NGT) aimed at significantly en-hancing motor capabilities, physiological mental/physical health, and quality of life.